Ovarian Stimulation Protocols for IVF: Antagonist vs Long Agonist Explained

Controlled ovarian stimulation is the first major step of every IVF cycle, and the protocol chosen affects safety, patient comfort and how the cycle is managed. For gynaecologists moving into reproductive medicine, understanding the two main protocols, and when each is used, is a core skill.

Key takeaways

• The GnRH antagonist protocol is the preferred choice for most patients in current ESHRE guidance, with similar efficacy and better safety than the long agonist protocol.
• Gonadotropin doses should be individualised using AMH, antral follicle count, age and previous response.
• An agonist trigger with a freeze-all strategy is a key tool for preventing OHSS in high responders.

What ovarian stimulation aims to do

Stimulation uses gonadotropins (FSH, with or without LH activity) to grow several follicles at once, while a GnRH analogue prevents a premature LH surge. The goal is a safe number of mature oocytes for the individual patient, not the highest possible number.

The GnRH antagonist protocol

In the antagonist protocol, gonadotropins start on day 2 or 3 of the cycle, and a GnRH antagonist is added once follicles grow (a fixed day-5/6 start or a flexible start based on follicle size).

Key features:

• Shorter treatment with fewer injections
• Rapid suppression of the LH surge without a long down-regulation phase
• The option of a GnRH agonist trigger instead of hCG, which considerably lowers the risk of ovarian hyperstimulation syndrome (OHSS)

The European Society of Human Reproduction and Embryology (ESHRE) ovarian stimulation guideline recommends the antagonist protocol for predicted normal and high responders, because efficacy is comparable to the long agonist protocol while safety is better.

The long GnRH agonist protocol

In the long protocol, a GnRH agonist is started in the mid-luteal phase of the previous cycle. After pituitary down-regulation is confirmed, gonadotropin stimulation begins.

Key features:

• Predictable cycle scheduling, which some clinics find useful for planning
• Longer treatment and more injections
• Higher OHSS risk in high responders, because an agonist trigger cannot be used

It is still used in selected situations, for example in some patients with endometriosis or according to clinic experience, but it is no longer the default choice in most guidelines.

Individualising the gonadotropin dose

Before stimulation, ovarian reserve is assessed with anti-Müllerian hormone (AMH) and antral follicle count (AFC), along with age and any previous response. This helps classify the patient as a predicted low, normal or high responder.

Practical principles:

• Avoid routinely high starting doses; for predicted normal responders, moderate doses are usually adequate
• In predicted high responders (for example many women with PCOS), use lower doses and an antagonist protocol
• In predicted low responders, very high doses rarely add benefit; counselling about realistic expectations matters

Monitoring and trigger

Monitoring combines transvaginal ultrasound follicle tracking with hormone levels where useful. The final trigger is usually given when several lead follicles reach around 17–18 mm. The choice between hCG and an agonist trigger depends on OHSS risk, and in high-risk cycles a freeze-all strategy is often used.

Preventing OHSS

OHSS is the most important safety concern of stimulation. Prevention relies on:

• Identifying high responders before starting
• Using an antagonist protocol with careful dosing
• Using an agonist trigger and freezing all embryos when the response is excessive
• Clear patient information about warning symptoms after oocyte retrieval

The regulatory context in India

Under the ART (Regulation) Act 2021, IVF procedures such as oocyte retrieval may only be carried out in a registered Level 2 ART clinic, with written informed consent, and the clinic must keep records of each cycle. Clinicians should also follow the limits set out in the Act and Rules, including those on the number of embryos transferred and on oocyte donation.

Frequently asked questions

Is the antagonist protocol always better than the long agonist protocol?

Not always, but for most patients it offers similar results with better safety, which is why current guidelines prefer it. The long protocol remains an option in selected cases.

Does a higher gonadotropin dose mean more pregnancies?

No. Beyond an individualised dose, more medication increases cost and risk without clear benefit. Dosing should be based on ovarian reserve and previous response.

Can stimulation protocols be learned from books alone?

Theory is essential, but protocol planning, scan interpretation and trigger decisions are best learned through supervised case discussions and clinical exposure.

Learn stimulation planning with ReproNest

ReproNest's Fellowship in Reproductive Medicine covers stimulation protocols, follicle monitoring, trigger decisions and OHSS prevention through case-based teaching and supervised clinical exposure at registered partner ART clinics. Read about eligibility, curriculum and career paths, or contact us for batch details.

This article is educational content for healthcare professionals and trainees. It is not medical advice and does not replace clinical judgement, current guidelines or the ART (Regulation) Act 2021 and Rules 2022.